MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-PB-12-0012394
Consern Pharma Limited - pharma in Ludhiana, Punjab, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹100.37 Cr
▼ 2% YoY
Net profit · FY 2025
₹9.64 Cr
Net margin 9.6%
EBITDA · FY 2025
₹15.1 Cr
EBITDA margin 15%
Authorised capital
₹35 Lakh
Registered with MCA
Paid-up capital
₹30.77 Lakh
Issued & subscribed
Open charges
₹8 Cr
Satisfied ₹16.69 Cr
Company age
25 yrs
Est. 2001
Employees · EPFO
504
Provident fund records
About Consern Pharma Limited
Data last updated:
Consern Pharma Limited is a public limited company based in Ludhiana, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 October 2001 and has been in existence for over 25 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24232PB2001PLC024715. Its GSTIN is 03AABCC7730R1ZF (Punjab). The company holds 10 GST registrations, all of them active.
The company has an authorised share capital of ₹35 Lakh and a paid-up capital of ₹30.77 Lakh. It was formerly known as Consern Pharma Private Limited. It is led by directors including Kuljive Mahajan (Managing Director) and Seema Mahajan (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 308 – C Bhai Randhir Singh Nagar, Ludhiana, Punjab, India – 141012.
As per the financials filed for FY 2025, the company reported a revenue of ₹100.37 Cr, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹9.64 Cr (net margin 9.6%) and EBITDA of ₹15.1 Cr (EBITDA margin 15%). Revenue has grown at a compounded annual rate (CAGR) of 19% over three years and 17% over five years.
The company has about 504 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Consern and Consern Pharma. As per MCA filings, the company has open charges of ₹8 Cr and satisfied charges of ₹16.69 Cr on record. Court records list 60 cases involving the company, including 46 filed by the company and 14 filed against it; 15 cases are pending. The company has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹14.7 Lakh; the latest was in March 2019. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 2 smaller; the largest is Nabros Pharma Private Limited with revenue of ₹101.03 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2020, listing 369 overdue payments to 18 micro and small suppliers.
Consern Pharma Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-PB-12-0012394). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website consernpharma.com.
Company Details of Consern Pharma Limited
CIN U24232PB2001PLC024715
Registration Number 024715
Incorporation Date 17 October 2001
ROC Chandigarh
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-PB-12-0012394
CIN History
Consern Pharma has one previous CIN (Corporate Identification Number): U24232PB2001PTC024715. The current CIN is U24232PB2001PLC024715, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232PB2001PLC024715 | Current |
| U24232PB2001PTC024715 | Previous |
Key People
Kuljive Mahajan Managing Director Seema Mahajan Whole-Time Director Riaz K Mahajan Additional Director Recognitions & Rankings of Consern Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address308 – C Bhai Randhir Singh Nagar, Ludhiana, Punjab, India – 141012
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Consern Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands
Consern Pharma operates two associated brands: Consern and Consern Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Consern is an R&D company focused on manufacturing drugs for various therapeutic areas. | consern.in | |
| Pharmaceutical manufacturing and research in Neuro-Psychiatry and other healthcare segments. | consernpharma.com |
Business Activity
The main business activity of Consern Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Financials of Consern Pharma Limited
FY 2024 filings availableConsern Pharma Limited reported revenue of ₹100.37 Cr (down 2% YoY) for FY 2025.
Revenue · FY 2025
₹100.37 Cr ▼ 2%
Net profit · FY 2025
₹9.64 Cr margin 9.6%
EBITDA · FY 2025
₹15.1 Cr margin 15%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 2%
3 years · compounded
▲ 19%
5 years · compounded
▲ 17%
EBITDA CAGR growth
1 year
▼ 32%
3 years · compounded
▲ 19%
5 years · compounded
▲ 32%
Revenue fell 2% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 17%. EBITDA fell 32% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profit and Loss Statement | ||
| Revenue from Operations | •••• | |
| Other Income | •••• | |
| Total Revenue | •••• | |
| Cost of Materials Consumed | •••• | |
| Employee Benefit Expense | •••• | |
| Finance Costs | •••• | |
| Depreciation and Amortisation | •••• | |
| Other Expenses | •••• | |
| Total Expenses | •••• | |
| EBITDA | ₹15.1 Cr | |
| Profit Before Tax | •••• | |
| Tax Expense | •••• | |
| Net Profit (PAT) | ₹9.64 Cr | |
| Balance Sheet | ||
| Share Capital | •••• | |
| Reserves and Surplus | •••• | |
| Net Worth (Total Equity) | •••• | |
| Long-term Borrowings | •••• | |
| Short-term Borrowings | •••• | |
| Trade Payables | •••• | |
| Total Liabilities | •••• | |
| Fixed Assets | •••• | |
| Investments | •••• | |
| Inventories | •••• | |
| Trade Receivables | •••• | |
| Cash and Bank Balance | •••• | |
| Total Assets | •••• | |
Financial Ratios
| Metrics | FY 2024-25 | FY 2020-21 to FY 2023-24in the company report |
|---|---|---|
| Profitability | ||
| EBITDA Margin | 15% | |
| Net Profit Margin | 9.6% | |
| Return on Equity (ROE) | •••• | |
| Return on Capital Employed (ROCE) | •••• | |
| Return on Assets (ROA) | •••• | |
| Liquidity and Debt | ||
| Current Ratio | •••• | |
| Quick Ratio | •••• | |
| Debt-to-Equity Ratio | •••• | |
| Interest Coverage Ratio | •••• | |
| Efficiency and Growth | ||
| Asset Turnover | •••• | |
| Receivable Days | •••• | |
| Payable Days | •••• | |
| Inventory Days | •••• | |
| Revenue Growth | •••• | |
| Net Profit Growth | •••• | |
Paid data: the figures shown as dots, and every line for FY 2020-21 to FY 2023-24, are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Consern Pharma are in the company report.
: available in the company report
Board of Directors of Consern Pharma Limited
Consern Pharma has 5 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Seema Mahajan | Whole-Time Director | 17 Oct 2001 | 25 Years 0 Months | Current |
| Kuljive Mahajan | Managing Director | 01 Apr 2004 | 22 Years 6 Months | Current |
| Riaz K Mahajan | Additional Director | 01 Jun 2025 | 1 Years 4 Months | Current |
| Atul Bhatara | Director | 01 Oct 2024 | 2 Years 0 Months | Current |
| Suresh Goel Also directs: Nirman Fincap Private Limited, Lumikei Med Private Limited | Additional Director | 01 Sep 2025 | 1 Years 1 Months | Current |
Peer Comparison
Consern Pharma Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nabros Pharma Private Limited | ₹101.03 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Ahmedabad, Gujarat, India |
| Instapill Private Limited | ₹100.92 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Bangalore, Karnataka, India |
| Sotac Pharmaceuticals Limited | ₹100.88 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Sanand, Gujarat, India |
| Lake Chemicals Private Limited | ₹100.59 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Bangalore, Karnataka, India |
| Credo Life Sciences Private Limited | ₹100.47 Cr (FY 2024) | •••• | •••• | 22.0% | •••• | Hyderabad, Telangana, India |
| Consern Pharma Limited this company | ₹100.37 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Ludhiana, Punjab, India |
| Medibios Laboratories Limited | ₹100.12 Cr (FY 2023) | •••• | •••• | -2.0% | •••• | |
| Synokem Lifesciences Private Limited | ₹99.46 Cr (FY 2025) | •••• | •••• | 108.0% | •••• | New Delhi, Delhi, India |
Peers are the companies nearest to Consern Pharma by revenue, above and below it, in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details
Consern Pharma Limited is audited by DASS KHANNA & CO for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| DASS KHANNA & CO | Locked | Locked | Locked |
: available in the company report
Ownership and Shareholding
: available in the company report
Charges & Borrowings
Open charges
₹8 Cr
Satisfied charges
₹16.69 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jan 2025 | Others | ₹8 Cr | Open |
| 26 Feb 2020 | Indian Overseas Bank | ₹7.96 Cr | Satisfied |
| 22 Apr 2019 | Others | ₹50 Lakh | Satisfied |
| 07 Oct 2017 | Hdfc Bank Limited | ₹6.7 Cr | Satisfied |
| 03 Jul 2010 | Indian Overseas Bank | ₹40 Lakh | Satisfied |
Total charge records: 7 View all charges
Deals & Funding
Consern Pharma Limited has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹14.7 Lakh; the latest was in March 2019.
Total deals
13
Secondary share transfers
12
Funding round
1
Disclosed funding
₹14.7 Lakh
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2019 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 2 individuals |
| Nov 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Oct 2016 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: an individual |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Jul 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
: available in the company report
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases
Consern Pharma Limited has 60 court cases on record: 46 filed by Consern Pharma, 14 filed against it. 15 cases are pending and 45 are disposed.
Total cases
60
Filed by the company
46
Filed against the company
14
Pending
15
Disposed
45
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 51 | 7 | 11 |
| High courts | 9 | 7 | 4 |
Cases on record (5 of 60)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed against the company by Sun Pharma Laboratories Ltd. | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Sun Pharma Laboratories Ltd | Pending |
| High Court of Delhi | Commercial suit | Filed by the company against Ikon Pharmachem Private Limited & Ors. | Pending |
| District court, South East, Delhi | Commercial suit | Filed by the company against Concertina Pharma Private Limited and Ors. | Pending |
| High Court | Court case (IP-COM) | Filed against the company by A N Pharmacia Laboratories Private Limited | Disposed |
: available in the company report
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays
Consern Pharma Limited has 4 MSME Form 1 returns on record between 2019 and 2020, listing 369 overdue payments to 18 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 18)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Resonance Laboratories Private Limited | •••• | •••• | •••• |
| Elnova Pharma | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Roaq Chemicals Pvt. Ltd. | •••• | •••• | •••• |
| Bajaj Healthcare Limited | •••• | •••• | •••• |
: available in the company report
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance
Consern Pharma Limited has a workforce of 504 employees as of Sep 25, 2025.
Employee count
504
Active EPFO establishments
1
Employee growth
7.69%
: available in the company report
Recent Activity
Consern Pharma Limited has 11 board changes on record since 2001: 7 appointments and 4 cessations. The latest: Suresh Goel was appointed as Additional Director on 01 Sep 2025.
Appointed
Suresh Goel was appointed as Additional Director.
Appointed
Riaz K Mahajan was appointed as Additional Director.
Charges
A charge with Others amounted to Rs. 800.00 Lakh with Charge ID 101033908 was registered on 15 Jan 2025.
Charges
A charge registered on 26 Feb 2020 via Charge ID 100333938 with Indian Overseas Bank was fully satisfied on 16 Dec 2024.
Appointed
Atul Bhatara was appointed as Director.
Appointed
Ridhima Bahl was appointed as Director.
AGM
Consern Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge registered on 22 Apr 2019 via Charge ID 100268831 with Others was fully satisfied on 16 Sep 2024.
Ceased
Seema Mahajan ceased to be Director.
Filing
Consern Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chandigarh.
Charges
A charge with Indian Overseas Bank of Rs. 796.50 Lakh registered on 26 Feb 2020 with Charge ID 100333938 was modified on 09 Sep 2022.
Charges
A charge registered on 07 Oct 2017 via Charge ID 100154159 with Hdfc Bank Limited was fully satisfied on 02 Jan 2021.
19 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts
: available in the company report
Subsidiaries & Group Companies
: available in the company report
GST Compliance
Consern Pharma has 10 GST registrations: 10 active. The first 4 active GSTINs are listed below.
Total GSTINs
10
Active
10
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AABCC7730R1ZF | Punjab | Active | 01 Jul 2017 |
| 10AABCC7730R1ZK | Bihar | Active | 01 Jul 2017 |
| 08AABCC7730R1Z5 | Rajasthan | Active | 19 Feb 2021 |
| 09AABCC7730R1Z3 | Uttar Pradesh | Active | 04 May 2021 |
: available in the company report
MCA Filings & Documents
: available in the company report
Frequently Asked Questions
Consern Pharma is an active public limited company based in Ludhiana, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 October 2001 (25+ years old) and is registered under CIN U24232PB2001PLC024715.
Consern Pharma has 5 current directors:
- Kuljive Mahajan - Managing Director
- Seema Mahajan - Whole-Time Director
- Riaz K Mahajan - Additional Director
- Atul Bhatara - Director
- Suresh Goel - Additional Director
The latest financial statements of Consern Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Consern Pharma is 03AABCC7730R1ZF, registered in Punjab. The company has 10 GST registrations in all, of which 10 are active. Other active GSTINs include 10AABCC7730R1ZK (Bihar), 08AABCC7730R1Z5 (Rajasthan), 09AABCC7730R1Z3 (Uttar Pradesh).
The CIN (Corporate Identification Number) of Consern Pharma is U24232PB2001PLC024715. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Consern Pharma has 60 court cases on record: 46 filed by the company and 14 filed against it. 15 are pending. Most are in the district courts.
Consern Pharma was incorporated on 17 October 2001, making it 25+ years old. It is registered with the Registrar of Companies, Chandigarh.
Consern Pharma has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹14.7 Lakh; the latest was in March 2019.
The peers of Consern Pharma by revenue are Nabros Pharma Private Limited, Instapill Private Limited, Sotac Pharmaceuticals Limited, Lake Chemicals Private Limited, Credo Life Sciences Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Suresh Goel was appointed as Additional Director on 01 Sep 2025. Riaz K Mahajan was appointed as Additional Director on 01 Jun 2025. Atul Bhatara was appointed as Director on 01 Oct 2024. Consern Pharma has 11 board changes on record in total.
Yes, Consern Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-PB-12-0012394).
Consern Pharma has 4 MSME Form 1 returns on record between 2019 and 2020, listing 369 overdue payments to 18 micro and small suppliers. The latest return was filed on 26 Jun 2020.